Eduardo Schenberg, PhD’s Post

Absolutely, there's a profound journey ahead. Research is to be the compass guiding us towards optimal delivery, minimizing potential challenges linked to widespread psychedelic use. In the realm of transformative decisions, driven by economics, politics, and policies, the clinical use of psychedelics is no exception. As Jeffrey rightly declared, the "train has left the station." Therefore, it’s our duty as clinicians to immerse ourselves in knowledge, becoming torchbearers of education for our patients and clients. I've witnessed the intersection of expertise in child, addiction, forensic, and public health psychiatry when the spotlight turned to our stance on marijuana. Less than a decade later, scientific literature echoes the concerns many of us voiced. In light of this experience, my position on the clinical use of psychedelics encompasses two essential imperatives: 1. Bridging Knowledge Gaps: SWEET’s vision aligns with closing the divide between cutting-edge science and clinicians' current awareness. Despite existing studies on psychedelics, we yearn for better design and more rigorous exploration. 2. Disseminating Accurate Information: Counteracting misinformation is critical. Our seminars on psychedelics for clinicians, the next on January 10th at 8 pm, are a beacon. It's SWEET Institute’s vision in action—arming clinicians with knowledge to empower themselves and guide patients. We cannot entrust psychedelics to non-clinicians, echoing Jeffrey Lieberman’s sentiment. To achieve this, mental health clinicians must be informed, ensuring we lead with wisdom and responsibility.

Nice article in the FT about the challenges and opportunities of schizophrenia drug development. And why we must persist! https://lnkd.in/epM-TBn6

Institute for Clinical and Economic Review (ICER) asking for PUBLIC COMMENTS publiccomments@icer.org What do you think? From Psychedelic Alpha “In short: ICER is pessimistic regarding the level of clinical evidence provided by Lykos Therapeutics, highlighting various concerns that range from trial design and conduct issues through to potential ethical and safety problems. While the organisation is generally relaying concerns it has heard from parties with ‘firsthand’ and ‘secondhand’ experience or knowledge of the trials, it’s hard not to see certain sections as scathing. ICER goes on to deem the clinical evidence to be of ‘low certainty’, which means it’s ‘insufficient’ in terms of feeding into a determination of comparative clinical effectiveness. That means that ICER’s cost effectiveness analyses are all exploratory. While that exploratory analysis does find MDMA-AP to be ‘less costly, more effective’ versus placebo, ICER is keen to remind readers that its analysis is somewhat hamstrung by its low certainty in the clinical evidence.” https://lnkd.in/endg-h_U

🔬 Embrace the chance to enlighten yourself with our breakthrough material on the uncharted dosage domain of Esketamine Spravato - a promising treatment option that's changing the landscape of clinical pharmacology. 💊 🧐 Our latest piece deciphers the complexities related to the appropriate dosing of this novel drug, enhancing your understanding and equipping you better to handle discussions about this treatment option. Your insights could make all the difference. 👩⚕️ Whether you're a clinician striving for best patient outcomes, a medical student keeping up with cutting-edge treatments or a health enthusiast interested in novel pharmacological advancements, this is an article you don't want to miss! 💡 Explore the not-so-mystifying-anymore world of Esketamine Spravato dosage at the link below. #Esketamine #ClinicalPharmacology #Medicine #Spravato #MentalHealthAwareness https://lnkd.in/eckcd4iQ

Exciting news! I'm thrilled to share our latest research, "Systematic Review on Intentional Non-Medical Fentanyl Use Among People Who Use Drugs," published in Frontiers in Psychiatry. https://lnkd.in/g_GPEW6g #FentanylUse #OpioidCrisis #PublicHealth #ResearchImpact #SystematicReview

I need my Ativan, Atavin, Ativan I rely on this 💊in acute situations and whenever these shortages happen they comprise patient care and put my staff and other patients at risk #psychiatry #psychiatrist #doctor #medications #shortages #mentalhealth #mentalhealthprofessionals #mentalhealthtips #mentalhealtheducation https://lnkd.in/e2MxJpn5.

Our research continues to push science forward. Recently, CNS Drugs published the full results of a Teva study demonstrating the long-term safety and tolerability of a treatment option for patients living with #schizophrenia. Approximately 24 million people worldwide are living with #schizophrenia and have to adapt to the challenges that come with living with this condition. The results of this study serve as another proof point of our ongoing commitment to helping address unmet challenges in #schizophrenia for a diverse range of patients because #WeAreAllInForBetterHealth! https://lnkd.in/e2VqSfXX #TogetherWeCanHelpPatients #TevaPharm #InnovativeMedicines #TevaRnDThePlaceToBe

New Drug for treatment of Schizophrenia approved by US FDA 💊 Cobenfy (xanomeline and trospium chloride) capsules for oral use. ➡ First antipsychotic drug approved to treat schizophrenia that targets cholinergic receptors. ⚠ Prescription warnings: Urinary retention, Increased heart rate, decreased gastric movement, angioedema. ❌ Not to be used by patients with hepatic impairment, patients with urinary retention, moderate to severe kidney or liver disease, gastric retention ❗ Risk of Liver Damage ⛔ Most common side effects: Nausea, Vomiting, Indigestion, Constipation, Hypertension, Tachycardia, Dizziness, GERD ✅ The approval of Cobenfy was granted to Bristol-Myers Squibb Company Source: https://lnkd.in/gBy2Vhyf

Psilocybin Get Canadian Export License in Psychedelic Race. Canada has licensed a startup to export psychedelics to Australia for patient use, the latest milestone to help supply medical psychedelic medicines. Read the full article here: https://buff.ly/3XdyvHy #MentalHealthAwareness #trauma #ptsd #MDMA #addiction #depression #psilocybin #psychiatry #psychology #psychedelictherapy #psychedelics #medicine #innovation #neuroscience #event #webinar

Our perspective paper on switching strategies from second and third generation antipsychotics to cariprazine was recently published in Frontiers in Psychiatry and is available for download: https://lnkd.in/dP-6dHFt